AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have earned an average rating of “Moderate Buy” from the twelve brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $76.3636.

A number of analysts have recently weighed in on ANAB shares. Piper Sandler upped their price target on shares of AnaptysBio from $67.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, January 21st. Wall Street Zen raised shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 25th. Stifel Nicolaus increased their target price on shares of AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Finally, Leerink Partners increased their target price on shares of AnaptysBio from $66.00 to $85.00 and gave the company an “outperform” rating in a research note on Tuesday.

Insider Activity at AnaptysBio

In related news, insider Eric J. Loumeau sold 10,000 shares of the stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total transaction of $540,000.00. Following the completion of the sale, the insider directly owned 12,835 shares of the company’s stock, valued at $693,090. This represents a 43.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John P. Schmid sold 20,645 shares of the stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the sale, the director directly owned 31,622 shares of the company’s stock, valued at approximately $1,774,310.42. This represents a 39.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 48,324 shares of company stock valued at $2,787,594 over the last ninety days. Insiders own 33.50% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

A number of large investors have recently made changes to their positions in ANAB. Affinity Asset Advisors LLC acquired a new stake in shares of AnaptysBio during the fourth quarter valued at approximately $21,559,000. JPMorgan Chase & Co. raised its holdings in shares of AnaptysBio by 1,631.6% during the second quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock valued at $5,497,000 after acquiring an additional 233,325 shares during the period. Voloridge Investment Management LLC raised its holdings in shares of AnaptysBio by 2,358.3% during the fourth quarter. Voloridge Investment Management LLC now owns 229,137 shares of the biotechnology company’s stock valued at $11,109,000 after acquiring an additional 219,816 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in shares of AnaptysBio by 145.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 370,458 shares of the biotechnology company’s stock valued at $11,343,000 after acquiring an additional 219,648 shares during the period. Finally, Soleus Capital Management L.P. raised its holdings in shares of AnaptysBio by 214.6% during the second quarter. Soleus Capital Management L.P. now owns 321,040 shares of the biotechnology company’s stock valued at $7,127,000 after acquiring an additional 218,988 shares during the period.

AnaptysBio Trading Up 5.4%

Shares of NASDAQ:ANAB opened at $65.73 on Friday. The company has a 50 day moving average of $60.87 and a 200-day moving average of $49.56. The firm has a market cap of $1.91 billion, a P/E ratio of -126.40 and a beta of 0.40. AnaptysBio has a twelve month low of $11.40 and a twelve month high of $71.67.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.69. The company had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. Equities research analysts forecast that AnaptysBio will post -3.15 EPS for the current year.

AnaptysBio announced that its board has approved a stock repurchase plan on Friday, March 27th that allows the company to buyback $100,000.00 billion in shares. This buyback authorization allows the biotechnology company to purchase up to 5,352,316.2% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.